The funding for 2010 will go to companies seeking to bridge the 'valley of death' between Phase II funding and venture capital or commercialization.
The grants are aimed at stimulating private sector advances and partnerships with non-profit institutions and universities.
The $10 million in 2010 will fund diagnostics, prognostics, imaging tools, and therapeutics needing help to make it to the market.
The company plans to use the $417,000 grant to develop assays for monitoring drug interactions.
The NHGRI funds will go to development of a single molecule analyzer.
The NHGRI grant will fund software development for cancer mutation analysis.
The firm will use the $250,000 fast-track grant to develop its tumor testing system.
The $600,000 award also strengthens Inviragen's ties to UW-Madison. The company's CSO maintains an academic appointment and a research lab within the School of Veterinary Medicine, which has collaborated with Inviragen on other projects.
The bill to reauthorize the science funding programs through 2023 will move to the full Senate.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.